Morgan Stanley initiates Attovia stock with overweight rating
Morgan Stanley has started covering Attovia Therapeutics (NASDAQ:ATTO) with an overweight rating and has set a price target of $39.00. The current stock price stands at $20.70, indicating considerable upside potential according to the analyst's target. However, InvestingPro data suggests the shares could be overvalued when compared to their Fair Value estimate.
The biotech firm operates with a market capitalization of $890.7 million. Attovia leverages its ATTOBODY platform to develop advanced therapeutics, primarily targeting a ligand called IL-31 for the treatment of chronic itch. This focus is driven by the success of Galderma's Nemluvio, which is anticipated to achieve over $4 billion in annual revenue for conditions such as atopic dermatitis and prurigo nodularis.
Morgan Stanley identified certain shortcomings in Nemluvio that Attovia aims to rectify through precise engineering of its candidates and a ligand-targeting strategy. Positive clinical results with a monospecific antibody targeting IL-31 are expected to bolster confidence in Attovia's early-stage bispecific therapy, which targets both IL-31 and IL-13.
The firm highlighted the significant market opportunity within chronic itch indications, which span millions of patients beyond Nemluvio's current indications. According to InvestingPro Tips, Attovia has a stronger financial position with more cash than debt and liquid assets exceeding short-term obligations—vital considerations for a company in the developmental phase.
The firm also noted the potential for positive readthrough to Attovia's developing multispecific antibody assets. Earlier this year, Attovia Therapeutics Inc. successfully completed its initial public offering, raising $289 million. The shares debuted at $21, surpassing the IPO price of $17 and resulting in a market value of nearly $904 million immediately following the offering.
These financial milestones underscore the company's growth potential and market interest, as reflected in the IPO's significant success.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
